Humira In 2023: The $17bn Biosimilar Opportunity

Landmark LOE Looms In US; Several Adalimumab Launches Expected Throughout Year

 
• By David Wallace
  
2023 Dial With Dollar Symbol
Humira’s loss of US exclusivity in 2023 represents the biggest opportunity yet for biosimilars • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products